778 results on '"Antigens, Human Platelet immunology"'
Search Results
2. Severe neonatal thrombocytopenia due to anti-HPA-4b alloantibodies: Third report described in a Caucasian mother.
- Author
-
Petermann R, Bianchi F, Saib L, Ferré N, Francelle N, Oudin O, Chenet C, Mammasse Y, Jallu V, Chaussade A, Cornu A, Dubray L, and Mailloux A
- Subjects
- Humans, Female, Infant, Newborn, Adult, Pregnancy, Male, Platelet Transfusion, White People, Isoantibodies blood, Isoantibodies immunology, Thrombocytopenia, Neonatal Alloimmune immunology, Thrombocytopenia, Neonatal Alloimmune blood, Antigens, Human Platelet immunology, Antigens, Human Platelet genetics
- Abstract
Background: Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) results from maternal platelet alloimmunization against paternal antigens inherited by the fetus, most often due to the Human Platelet Antigen (HPA)-1 system in Caucasians. We investigated in 2023, a 30-year-old Caucasian woman Gravida 2 Para 1 who gave birth at 35 weeks of gestation to a male (body weight 2210 g) without signs of bleeding. A severe thrombocytopenia (platelet count at 3 G/L) was discovered incidentally a few hours after delivery in the context of the management of a respiratory distress. The newborn recovered after one platelet concentrate transfusion and normalized his platelet count at Day 5., Study Design and Methods: FNAIT investigation was performed according to guideline recommendations. Platelet genotyping was carried out by multiplex PCR. Maternal serological investigation included Monoclonal Antibody-specific Immobilization of Platelet Antigens method (MAIPA) and Luminex technology., Results: Parental and newborn genotyping pointed out an HPA-4 incompatibility between the mother and the newborn and the father. Serological investigation revealed an anti-HPA-4b alloantibody confirming the diagnosis of neonatal alloimmune thrombocytopenia., Conclusion: We described the third case of anti-HPA-4b alloantibody discovered in a Caucasian mother. This case strengthens the need for reference laboratory to genotype a panel of HPA alleles reflecting local genetic population diversity and for crossmatch of maternal serum with fresh paternal platelets in clinical suspected cases of neonatal alloimmune thrombocytopenia., (© 2024 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.)
- Published
- 2024
- Full Text
- View/download PDF
3. Should HLA and HPA-matched platelet transfusions for patients with Glanzmann Thrombasthenia or Bernard-Soulier syndrome be standardized care? A Dutch survey and recommendations.
- Author
-
Huisman EJ, Holle N, Schipperus M, Cnossen MH, de Haas M, Porcelijn L, and Zwaginga JJ
- Subjects
- Humans, Netherlands, Surveys and Questionnaires, Male, Female, Child, Platelet Transfusion, Antigens, Human Platelet immunology, Thrombasthenia therapy, Thrombasthenia immunology, Bernard-Soulier Syndrome therapy, Bernard-Soulier Syndrome immunology, HLA Antigens immunology
- Abstract
Background: Glanzmann thrombasthenia (GT) and Bernard-Soulier syndrome (BSS) patients require frequent platelet transfusions and hence have an increased risk for alloimmunization against donor Human Leukocyte Antigens (HLA) when no HLA-matching is performed. Knowing that Human Platelet Antigens (HPA) are located on the platelet glycoproteins that can be absent in these patients, preventive HPA-matching may also be considered. Uniform recommendations on this topic lack in transfusion guidelines making standard practice unclear, therefore, we aimed to provide a framework for matched platelet transfusions., Study Design and Methods: We conducted a targeted literature search and a national survey of Dutch (pediatric) hematologists from July to September 2021., Results: We found 20 articles describing platelet transfusion policies in 483 GT-patients and 29 BSS-patients, both adults and children. Twenty surveys were returned for full analysis. All responders treated patients with platelet disorders, including GT (n = 36 reported) and BSS (n = 29 reported). Of respondents, 75% estimated the risk of antibody formation as "likely" for HLA and 65% for HPA. Formation of HLA antibodies was reported in 5 GT and in 5 BSS-patients, including one child. Fifteen respondents gave preventive HLA-matched platelets in elective setting (75%). Three respondents additionally matched for HPA in GT-patients (15%). Main argument for matched platelet transfusions was preventing alloimmunization to safeguard the effectivity of 'random' donor-platelets in acute settings., Conclusion: Elective HLA-matching for GT and BSS-patients is already conducted by most Dutch (pediatric) hematologists. HPA-matching is mainly applied when HPA-antibodies are formed. Based on the current literature and the survey, recommendations are proposed., (© 2024 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.)
- Published
- 2024
- Full Text
- View/download PDF
4. Generation of human antibodies targeting human platelet antigen (HPA)-1a.
- Author
-
Oosterhoff JJ, Linty F, Visser R, de Vos T, Hofstede-van Egmond S, van de Weerd M, Porcelijn L, de Haas M, van der Schoot E, and Vidarsson G
- Subjects
- Humans, Pregnancy, Female, Integrin beta3 immunology, B-Lymphocytes immunology, Antibodies, Monoclonal immunology, Blood Platelets immunology, Blood Platelets metabolism, Infant, Newborn, Antigens, Human Platelet immunology, Thrombocytopenia, Neonatal Alloimmune immunology, Isoantibodies immunology
- Abstract
Background: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a condition during pregnancy, which can lead to thrombocytopenia and a bleeding tendency with intracranial hemorrhage (ICH) being the most concerning complication in the fetus or neonate. An incompatibility between human platelet antigen (HPA)-1a accounts for the majority of FNAIT cases. Binding of HPA-1a-specific alloantibodies to their target on fetal platelets and endothelial cells can induce apoptosis of megakaryocytes, disrupt platelet function, and impair angiogenesis. Currently, there is no screening program to identify pregnancies at risk for severe disease. A better understanding of HPA-1a-specific antibody heterogeneity in FNAIT could aid in identifying pathogenic antibody properties linked to severe disease., Study Design and Methods: This study aimed to isolate HPA-1a-specific B-cells from an HPA-1a-alloimmunized pregnant woman. Using fluorescently labeled HPA-1a-positive platelets, single B-cells were sorted and cultured for 10 days to stimulate antibody production. Subsequently, supernatants were tested for the presence of antibodies by enzyme-linked immunosorbent assay and their reactivity towards HPA-1a-positive platelets. Amplification and sequencing of variable regions allowed the generation of monoclonal antibodies using a HEK-Freestyle-based expression system., Results: Three platelet-specific B-cells were obtained and cloned of which two were specific for HPA-1a, named D- and M-204, while the third was specific for HLA class I, which was named L-204., Discussion: This study outlined an effective method for the isolation of HPA-1a-specific B-cells and the generation of monoclonal antibodies. Further characterization of these antibodies holds promise for better understanding the pathogenic nature of alloantibodies in FNAIT., (© 2024 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB.)
- Published
- 2024
- Full Text
- View/download PDF
5. Anti-human platelet antigen-5b antibodies and fetal and neonatal alloimmune thrombocytopenia; incidental association or cause and effect?
- Author
-
Alm J, Duong Y, Wienzek-Lischka S, Cooper N, Santoso S, Sachs UJ, Kiefel V, and Bein G
- Subjects
- Antibodies, Female, Fetus, Humans, Infant, Newborn, Integrin beta3, Platelet Count, Pregnancy, Prenatal Care, Retrospective Studies, Antigens, Human Platelet immunology, Fetal Diseases diagnosis, Fetal Diseases immunology, Infant, Newborn, Diseases, Thrombocytopenia, Neonatal Alloimmune diagnosis, Thrombocytopenia, Neonatal Alloimmune immunology
- Abstract
Most cases of fetal and neonatal thrombocytopenia (FNAIT) are caused by maternal anti-human platelet antigen-1a antibodies (anti-HPA-1a). Anti-HPA-5b antibodies are the second most common antibodies in suspected FNAIT cases. Given the high prevalence of anti-HPA-5b antibodies in pregnant women delivering healthy newborns, the association with FNAIT may be coincidental. This review of the literature related to FNAIT using the MEDLINE database was conducted according to PRISMA guidelines. A retrospective analysis of a single-centre cohort of 817 suspected FNAIT cases was conducted. The pooled prevalence of anti-HPA-5b antibodies in unselected pregnant women of European descent was 1.96% (n = 3113), compared with 3.4% (n = 5003) in women with suspected FNAIT. We found weak evidence that a small proportion of pregnant women presenting with anti-HPA-5b antibodies will give birth to a newborn with mild thrombocytopenia. The neonatal platelet counts were not different between suspected FNAIT cases (n = 817) with and without maternal anti-HPA-5b antibodies. The prevalence of maternal anti-HPA-5b antibodies was not different between neonates with intracranial haemorrhage and healthy controls. The current experimental and epidemiological evidence does not support the hypothesis that anti-HPA-5b antibodies cause severe thrombocytopenia or bleeding complications in the fetus or newborn., (© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
6. Prevention of Fetal/Neonatal Alloimmune Thrombocytopenia in Mice: Biochemical and Cell Biological Characterization of Isoforms of a Human Monoclonal Antibody.
- Author
-
Mørtberg TV, Zhi H, Vidarsson G, Foss S, Lissenberg-Thunnissen S, Wuhrer M, Michaelsen TE, Skogen B, Stuge TB, Andersen JT, Newman PJ, and Ahlen MT
- Subjects
- Animals, Antibodies, Monoclonal administration & dosage, Female, Humans, Immunoglobulin G administration & dosage, Male, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Protein Isoforms, THP-1 Cells, Antigens, Human Platelet immunology, Integrin beta3 immunology, Isoantibodies blood, Thrombocytopenia, Neonatal Alloimmune immunology, Thrombocytopenia, Neonatal Alloimmune prevention & control
- Abstract
Maternal alloantibodies toward paternally inherited Ags on fetal platelets can cause thrombocytopenia and bleeding complications in the fetus or neonate, referred to as fetal and neonatal alloimmune thrombocytopenia (FNAIT). This is most commonly caused by Abs against the human platelet Ag (HPA)-1a in Caucasians, and a prophylactic regimen to reduce the risk for alloimmunization to women at risk would be beneficial. We therefore aimed to examine the prophylactic potential of a fully human anti-HPA-1a IgG1 (mAb 26.4) with modified Fc region or altered N-glycan structures. The mAb 26.4 wild-type (WT) variants all showed efficient platelet clearance capacity and ability to mediate phagocytosis independent of their N-glycan structure, compared with an effector silent variant (26.4.AAAG), although the modified N-glycan variants showed differential binding to FcγRs measured in vitro. In an in vivo model, female mice were transfused with platelets from transgenic mice harboring an engineered integrin β3 containing the HPA-1a epitope. When these preimmunized mice were bred with transgenic males, Abs against the introduced epitope induced thrombocytopenia in the offspring, mimicking FNAIT. Prophylactic administration of the mAb 26.4.WT, and to some extent the mAb 26.4.AAAG, prior to platelet transfusion resulted in reduced alloimmunization in challenged mice and normal platelet counts in neonates. The notion that the effector silent variant hampered alloimmunization demonstrates that rapid platelet clearance, as seen with mAb 26.4.WT, is not the sole mechanism in action. Our data thus successfully demonstrate efficient Ab-mediated immunosuppression and prevention of FNAIT by anti-HPA-1a monoclonal variants, providing support for potential use in humans., (Copyright © 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
7. Clinical characteristics of human platelet antigen (HPA)-1a and HPA-5b alloimmunised pregnancies and the association between platelet HPA-5b antibodies and symptomatic fetal neonatal alloimmune thrombocytopenia.
- Author
-
de Vos TW, Porcelijn L, Hofstede-van Egmond S, Pajkrt E, Oepkes D, Lopriore E, van der Schoot CE, Winkelhorst D, and de Haas M
- Subjects
- Adult, Female, Humans, Immunity, Maternally-Acquired, Infant, Newborn, Infant, Small for Gestational Age, Intracranial Hemorrhages etiology, Maternal-Fetal Exchange, Parity, Platelet Count, Pregnancy, Retrospective Studies, Surveys and Questionnaires, Antigens, Human Platelet immunology, Hemorrhage etiology, Histocompatibility, Maternal-Fetal, Integrin beta3 immunology, Isoantibodies immunology, Thrombocytopenia, Neonatal Alloimmune immunology
- Abstract
Fetal neonatal alloimmune thrombocytopenia (FNAIT) is caused by maternal alloantibodies directed against the human platelet antigens (mostly HPA-1a or HPA-5b) of the (unborn) child and can lead to severe bleeding. Anti-HPA-1a-mediated FNAIT shows a severe clinical outcome more often than anti-HPA-5b-mediated FNAIT. Given the relatively high prevalence of anti-HPA-5b in pregnant women, the detection of anti-HPA-5b in FNAIT-suspected cases may in some cases be an incidental finding. Therefore we investigated the frequency of anti-HPA-5b-associated severe bleeding in FNAIT. We performed a retrospective nationwide cohort study in cases with clinical suspicion of FNAIT. HPA antibody screening was performed using monoclonal antibody-specific immobilisation of platelet antigens. Parents and neonates were typed for the cognate antigen. Clinical data were collected by a structured questionnaire. In 1 864 suspected FNAIT cases, 161 cases (8·6%) had anti-HPA-1a and 60 (3·2%) had anti-HPA-5b. The proportion of cases with severe bleeding did not differ between the cases with anti-HPA-1a (14/129; 11%) and anti-HPA-5b (4/40; 10%). In multigravida pregnant women with a FNAIT-suspected child, 100% (81/81) of anti-HPA-1a cases and 79% (38/48) of anti-HPA-5b cases were HPA-incompatible, whereas 86% and 52% respectively were expected, based on the HPA allele distribution. We conclude that anti-HPA-5b can be associated with severe neonatal bleeding symptoms. A prospective study is needed for true assessment of the natural history of anti-HPA-5b mediated FNAIT., (© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
8. The first reported case of neonatal alloimmune thrombocytopenia due to low-frequency human platelet antigen-6b antibodies in the United Kingdom.
- Author
-
Hopkins M, Brookes J, Watson D, Wroe E, Guthrie P, Horler J, Anayattil K, Calvert A, and Poles A
- Subjects
- Adult, Blood Platelets immunology, Female, Humans, Infant, Newborn, Male, United Kingdom, Antigens, Human Platelet immunology, Isoantibodies immunology, Thrombocytopenia, Neonatal Alloimmune immunology
- Abstract
Background: Neonatal alloimmune thrombocytopenia (NAIT) is a potentially serious clinical condition caused by maternal alloantibodies directed to human platelet antigens (HPA), inherited from the father and expressed on fetal/neonatal platelets. We report a case of an otherwise well, full term child, with a profound thrombocytopenia (33 x 109/L). There was no bleeding or obvious explanation for the low platelet count. Samples were sent for the investigation of NAIT., Method: Serological investigations were performed on maternal serum taken at day (D)+4 and D+78. The platelet immunofluorescence test (PIFT) and monoclonal antibody immobilization of platelet antigens (MAIPA) assays were performed with a panel of HPA typed donor platelets and against paternal platelets in a crossmatch. HPA 1-6, -9 and -15 and HLA genotyping was performed by in-house PCR-sequence based typing (SBT) and next generation sequencing (NGS)., Results: HPA antibody screening of D+4 maternal serum indicated that platelet-specific antibodies were absent. HPA genotyping of the father and child revealed the presence of the low frequency HPA antigen (LFHPA), HPA-6b, which was absent in the mother. Maternal samples were crossmatched against paternal platelets and were positive by PIFT and glycoprotein (GP) IIb/IIIa and HLA class I in the MAIPA assay. The infant required no platelet transfusion support as the thrombocytopenia resolved spontaneously., Discussion: We conclude that the positive crossmatch reaction was due to anti-HPA-6b alloantibodies. This case further emphasizes the importance of platelet crossmatching and HPA genotyping of LFHPA in cases where there is a high clinical suspicion of NAIT but initial screening is negative., (© 2021 AABB.)
- Published
- 2021
- Full Text
- View/download PDF
9. New developments in fetal and neonatal alloimmune thrombocytopenia.
- Author
-
Bussel JB, Vander Haar EL, and Berkowitz RL
- Subjects
- Antigens, Human Platelet genetics, Cell-Free Nucleic Acids genetics, Drug Development, Female, Genotype, Glucocorticoids therapeutic use, Histocompatibility Antigens Class I, Humans, Immunoglobulin G immunology, Immunoglobulins, Intravenous therapeutic use, Integrin beta3 genetics, Integrin beta3 immunology, Maternal-Fetal Exchange immunology, Noninvasive Prenatal Testing methods, Prednisone therapeutic use, Pregnancy, Prenatal Diagnosis, Risk Assessment, Thrombocytopenia, Neonatal Alloimmune immunology, Thrombocytopenia, Neonatal Alloimmune therapy, Antigens, Human Platelet immunology, Immunologic Factors therapeutic use, Receptors, Fc antagonists & inhibitors, Thrombocytopenia, Neonatal Alloimmune diagnosis, Thrombocytopenia, Neonatal Alloimmune prevention & control
- Abstract
Fetal and neonatal alloimmune thrombocytopenia, the platelet equivalent of hemolytic disease of the fetus and newborn, can have devastating effects on both the fetus and neonate. Current management of fetal and neonatal alloimmune thrombocytopenia in a subsequent affected pregnancy involves antenatal administration of intravenous immune globulin and prednisone to the pregnant woman to prevent the development of severe fetal thrombocytopenia and secondary intracranial hemorrhage in utero. That therapy has proven to be highly effective but is associated with maternal side effects and is expensive. This commentary describes 4 advances that could substantially change the current approach to detecting and managing fetal and neonatal alloimmune thrombocytopenia in the near future. The first would be an introduction of a program to screen all antepartum patients in this country for pregnancies at risk of developing fetal and neonatal alloimmune thrombocytopenia. Strategies to implement this complex process have been described. A second advance is testing of cell-free fetal DNA obtained from maternal blood to noninvasively determine the fetal human platelet antigen 1 genotype. A third, in preliminary development, is creation of a prophylactic product that would be the platelet equivalent of Rh immune globulin (RhoGAM). Finally, a fourth major potential advance is the development of neonatal Fc receptor inhibitors to replace the current medical therapy administered to pregnant women with an affected fetus. Neonatal Fc receptor recycles plasma immunoglobulin G to increase its half-life and is the means by which immunoglobulin G crosses the placenta from the maternal to the fetal circulation. Blocking the neonatal Fc receptor is an ideal way to prevent maternal immunoglobulin G antibody from causing fetal and neonatal alloimmune thrombocytopenia in a fetus at risk of developing that disorder. The pertinent pathophysiology and rationale for each of these developments will be presented in addition to our thoughts relating to steps that must be taken and difficulties that each approach would face for them to be successfully implemented., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
10. A case report of prenatal diagnosis of fetal alloimmune thrombocytopenia: A CARE-compliant article.
- Author
-
Fu J, Yao R, and Yong W
- Subjects
- Adult, Antigens, Human Platelet blood, Antigens, Human Platelet immunology, Female, Fetal Diseases immunology, HLA Antigens blood, HLA Antigens immunology, Humans, Infant, Newborn, Platelet Count, Pregnancy, Thrombocytopenia, Neonatal Alloimmune immunology, Fetal Blood immunology, Fetal Diseases diagnosis, Prenatal Diagnosis methods, Thrombocytopenia, Neonatal Alloimmune diagnosis
- Abstract
Rationale: Fetal alloimmune thrombocytopenia (FAIT) is a serious life-threatening disease caused by platelet-antigen incompatibility between the mother and fetus. FAIT can lead to fetal thrombocytopenia, intracranial hemorrhage (ICH), fetal death and severe neurological disorders after birth. Noninvasive prenatal diagnosis technology has not been widely used in China, and thus few cases of FAIT can be diagnosed prenatally. In this study, we report a case of prenatal diagnosis and treatment of FAIT., Patient Concerns: A 29-year-old female was admitted at 32 weeks' gestational age (GA). Fetal ultrasound at 32 weeks' GA showed a hemorrhagic focus area in the left lateral ventricle and the sign of severe fetal anemia. Hence, fetal umbilical cord puncture was ordered to identify the etiology., Diagnoses: The fetal cord blood test revealed a normal hemoglobin level but severe fetal thrombocytopenia (platelet count, 23 × 109/L). Antibodies of human platelet antigens and human leukocyte antigens between mother and fetus were positive, and thus the diagnosis of FAIT was confirmed., Interventions: The patient refused intravenous immunoglobulin (IVIG) therapy owing to financial consideration. She was treated with dexamethasone acetate tablets (Xianju Company, China) 0.75 mg twice a day until delivery and cesarean section was performed at 34 weeks' GA. The newborn received postnatal anti-platelet antibody treatment., Outcomes: The platelet count of the newborn progressively decreased until the third day after birth and it increased to normal level after postnatal treatment. The neonatal cerebral ultrasound showed the area of hemorrhage was in the process of absorption. During the postnatal one-year follow-up, the neonate showed normal developmental milestones and had no abnormal signs of neurological symptoms., Lessons: For FAIT, the fetal umbilical cord puncture can be carried out by skilled fetal medical teams. Dexamethasone acetate tablets can be an alternative choice for patients from underdeveloped areas., Competing Interests: The authors have no conflicts of interests to disclose., (Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2021
- Full Text
- View/download PDF
11. Transplantation-mediated alloimmune thrombocytopenia successfully treated by retransplantation.
- Author
-
Aranda Escaño E, Prieto Calvo M, Perfecto Valero A, Ruiz Irastorza G, Gastaca Mateo M, and Valdivieso López A
- Subjects
- Antigens, Human Platelet immunology, Female, Follow-Up Studies, Humans, Lupus Erythematosus, Systemic pathology, Male, Middle Aged, Platelet Count methods, Purpura, Thrombocytopenic, Idiopathic complications, Purpura, Thrombocytopenic, Idiopathic immunology, Splenectomy adverse effects, Thrombocytopenia blood, Thrombocytopenia immunology, Tissue Donors, Transplant Recipients, Treatment Outcome, Liver Transplantation adverse effects, Lupus Erythematosus, Systemic complications, Reoperation methods, Thrombocytopenia etiology
- Abstract
Introduction: Transplantation-mediated alloimmune thrombocytopenia (TMAT) is a rare complication affecting the recipient of an organ from a donor with immune thrombocytopenia (ITP)., Methods: We present a case of TMAT following liver transplantation successfully treated by retransplantation, along with a review of previously published cases.Clinical presentation: The liver donor had lupus and ITP and died from an intracranial hemorrhage. The recipient's platelet count fell to 2 x10
9 /L on postoperative day 2. Due to the lack of response to medical treatment, emergency retransplantation was undertaken with a steady recovery of the platelet count within a few days., Discussion: Six additional cases of transplantation-mediated alloimmune thrombocytopenia after liver transplantation have been reported. In all cases, severe thrombocytopenia ensued within 3 days after liver transplantation. Four patients suffered hemorrhagic complications. Three patients died. Early retransplantation was needed in three out of four patients receiving a graft from a donor with ITP and splenectomy. All recovered shortly after the new graft was in place., Conclusion: Severe refractory transplantation-mediated alloimmune thrombocytopenia can develop in liver recipients from donors with ITP, especially those with previous splenectomy. Early retransplantation should be considered if there is no rapid response to medical therapy.- Published
- 2021
- Full Text
- View/download PDF
12. Minor impact of patient alloantibodies against human platelet antigen (HPA)-15 in the effectiveness of platelet transfusion: A pilot study.
- Author
-
Inoue H, Sakamoto R, Nishimiya H, Sakamoto H, Terasu S, Aminaka R, Koh Y, Takihara Y, Hirayama F, and Kuroishi A
- Subjects
- Aged, Antigens, CD blood, Blood Group Incompatibility, Female, GPI-Linked Proteins blood, GPI-Linked Proteins immunology, Humans, Isoantibodies immunology, Japan, Leukemia, Myeloid, Acute blood, Male, Middle Aged, Myelodysplastic Syndromes blood, Neoplasm Proteins blood, Pilot Projects, Statistics, Nonparametric, Antigens, CD immunology, Antigens, Human Platelet immunology, Isoantibodies blood, Leukemia, Myeloid, Acute immunology, Myelodysplastic Syndromes immunology, Neoplasm Proteins immunology, Platelet Transfusion adverse effects
- Abstract
Background: Alloantibodies against human platelet antigen (HPA)-15 are sometimes detected in patients with platelet transfusion refractoriness (PTR); however, little is known about their impact on PTR., Study Design and Methods: Two patients who possessed HPA-15 alloantibodies (Patient 1, anti-HPA-15b; Patient 2, anti-HPA-15a) and human leukocyte antigen (HLA) antibodies were enrolled. The efficacy of HPA-15-compatible vs -incompatible platelet transfusion was compared by focusing on ABO- and HLA-matched transfusions on the basis of the 24-hour corrected count increment (CCI-24 hours) for platelets. The titers of HPA-15 antibodies in the patients' sera were also monitored., Results: The patients received 71 and 12 ABO-compatible, HLA-matched platelet transfusions, respectively, during the monitoring periods. Among these transfusions, CCI-24 hours could be calculated in 27 and 10 transfusions, respectively, and the HPA-15 genotype of the donors was determined. There were no significant differences in the CCI-24 hours between the HPA-15 compatible and incompatible transfusions in both patients (P = .30 and .56, respectively, Mann-Whitney U test). There was no significant change in the HPA-15b antibody titer in Patient 1 during the monitoring period, while the HPA-15a antibody level in Patient 2 was undetectable at the end of the monitoring period, although the titer was low at the beginning., Conclusion: The efficacy of HPA-15-incompatible platelet transfusions was not necessarily inferior to that of HPA-15 compatible ones. Although the case number was limited, our results suggest that HPA-15 antibodies do not have a significant impact on the effects of platelet transfusion., (© 2020 AABB.)
- Published
- 2021
- Full Text
- View/download PDF
13. Slot blotting and flow cytometry: two efficient assays for platelet antibody screening among patients with platelet refractoriness.
- Author
-
Ameri Z, Vahidi R, Khaleghi M, Dehesh T, Sheikhbardsiri A, and Farsinejad A
- Subjects
- Adult, Antigens, Human Platelet immunology, Female, Humans, Male, Platelet Transfusion, Sensitivity and Specificity, Thrombocytopenia blood, Thrombocytopenia immunology, Blood Platelets immunology, Flow Cytometry methods, Isoantibodies blood, Thrombocytopenia diagnosis
- Abstract
Background and Objectives: Frequent platelet transfusion may lead to the formation of alloantibodies and immune-mediated platelet destruction. Currently, identifying economic and effective screening methods is necessary for the management of platelet transfusion while different tests were recommended. The present study aims to challenge the performance of slot blotting (SB) and flow cytometry (FC) assays in detecting immune platelet refractoriness., Materials and Methods: Sera from 118 patients who received blood components and were clinically suspected of platelet refractoriness were enrolled. Platelet-reactive antibodies were explored in parallel by SB, FC and monoclonal antibody-specific immobilization of platelet antigens (MAIPA) techniques. In a further study, chloroquine-treated platelets were incubated with MAIPA-positive serum, and then, the results of the SB and FC techniques were compared., Results: Using MAIPA as a reference, antibodies were detected in 51 sera, with specificity for human leucocyte antigens (HLA), human platelet antigens (HPA) or both HLA/HPA, in 27, 18 and 6 patients, respectively. The sensitivity and specificity of SB and FC were 86·3%, 88·1%, 82·4% and 95·5%, respectively. The Spearman correlation revealed significant (P < 0·001) correlations between FC (r = 0·763) and SB (r = 0·738) with MAIPA. In respect to HPA antibody detection, SB had 83·3% sensitivity and 92·6% specificity compared to 91·7% and 96·3% for FC while both approaches are acceptable (P < 0·001, r = 0·69; P < 0·001, r = 0·773) and can be recommended., Conclusions: The present study acknowledges that among the used methods, the flow cytometry's performance is the most appropriate, but slot blotting, with acceptable sensitivity, can be used as an acceptable and convenient procedure for platelet antibody screening., (© 2020 International Society of Blood Transfusion.)
- Published
- 2021
- Full Text
- View/download PDF
14. [Diagnosis and management of severe neonatal thrombocytopenia due to maternal alloimmunization against fetal platelet antigens: case study and literature review].
- Author
-
Toughza J, Agadr A, Nejjari M, and Ammari IA
- Subjects
- Adult, Female, Fetal Blood immunology, Humans, Immunoglobulin G immunology, Infant, Newborn, Male, Pregnancy, Severity of Illness Index, Thrombocytopenia, Neonatal Alloimmune immunology, Antigens, Human Platelet immunology, Isoantibodies immunology, Thrombocytopenia, Neonatal Alloimmune diagnosis
- Abstract
Thrombocytopenia is a common hematologic disorder in the neonatal period. It can occur in neonates hospitalized in the Intensive Care Unit and in preterm infants. It is characterized by a platelet count of less than 150.000/mm
3 . In the context of immune thrombocytopenia, neonatal thrombocytopenia due to maternal alloimmunization (estimated at 1 per 1000 live births) is not a rare event but it is often undiagnosed in minor forms. This is caused by maternal immunization against fetal platelet antigens inherited from the father and lacking in the mother. Maternal IgG alloantibodies cross the placenta causing fetal platelet destruction. In severe thrombocytopenia, consequences can be severe, with intracranial bleeding occurring in 10-30% of patients. Diagnosis is essentially based on clinical examination and must be suspected by pediatricians., Competing Interests: Les auteurs ne déclarent aucun conflit d'intérêts., (Copyright: Jihane Toughza et al.)- Published
- 2020
- Full Text
- View/download PDF
15. [Relevance of antibodies in hematopoietic stem cell transplantation: Antibodies anti-HLA, anti-platelets, anti-granulocytes, anti-erythrocytes and anti-MICA. Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
- Author
-
Delbos F, Blouin L, Bruno B, Crocchiolo R, Desoutter J, Detrait M, Nguyen-Lejarre KT, Giannoli C, Lemarié C, Renac V, Yakoub-Agha I, and Dubois V
- Subjects
- ABO Blood-Group System immunology, Antigens, Human Platelet immunology, Blood Platelets immunology, Erythrocytes immunology, Granulocytes immunology, HLA Antigens immunology, Histocompatibility Antigens Class I immunology, Humans, Antibodies immunology, Hematopoietic Stem Cell Transplantation methods
- Abstract
The presence of allo-antibodies in the serum of a recipient awaiting hematopoietic stem cell transplantation (HSCT) may have an impact on transfusion efficiency and/or donor choice, especially in the absence of an identical sibling donor. Prior to transplantation, donor specific anti-HLA (Human Leukocyte Antigen) antibodies (DSA) have a recognized effect on transplant outcome, correlated with the increasing MFI value and with the ability of such antibody to fix the complement fraction. Anti-platelet antibodies (anti-HLA class I and anti-HPA [Human Platelet Antigen]) are better involved in transfusion inefficiency and can be responsible for refractory status. ABO incompatibilities require a specific treatment of the graft in presence of high titer to avoid hemolytic adverse effects. Investigations of these antibodies should be carried out on a regular basis in order to establish appropriate transfusion recommendation, select an alternative donor when possible or adapt the source of cells. After transplantation, in case of delayed recovery or graft rejection, long term aplasia, persistent mixed chimerism or late release, and after elimination of the main clinical causes, a biological assessment targeted on the different type of antibodies will have to be performed in order to orient towards the cause or the appropriate therapy. Further studies should be carried out to determine the impact of anti-MICA antibodies and recipient specific anti-HLA antibodies, on the outcome of the transplantation., (Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
16. Application of lyophilised human platelets for antibody detection in solid phase red cell adherence assay.
- Author
-
Duan S, Wang M, Ding S, Chen Y, Wei S, Chen W, Zhang C, Li Y, and Wang H
- Subjects
- Biomarkers blood, Blood Specimen Collection, Case-Control Studies, Freeze Drying, Histocompatibility, Humans, Integrin beta3, Predictive Value of Tests, Thrombocytopenia blood, Thrombocytopenia immunology, Antigens, Human Platelet immunology, Blood Platelets immunology, Immune Adherence Reaction, Isoantibodies blood, Platelet Membrane Glycoproteins immunology, Thrombocytopenia diagnosis
- Abstract
Antibodies against human platelets cause a variety of thrombocytopenic disorders, which lead to potentially fatal haemorrhage. Therefore, their prompt detection is mandatory for successful patient treatment. Solid phase red cell adherence (SPRCA) assay allows for platelet antibody detection widely. However, preparation of fresh platelets with HLA-I and human platelet antigens (HPA)1-5,15 genotyped as target cells is inconvenient and fresh platelets have a short shelf life. In this study, the lyophilised human platelets for antibody detection in SPRCA were prepared. Firstly, platelets were resuspended in lyophilisation buffer and freeze-dried. Then the characteristics of lyophilised platelet were analysed. Rehydrated platelets were recovered with a mean rate of 80.91% ± 2.87%, and still retained spherical morphology. Indirect flow cytometry showed that glycoproteins IIb/IIIa, Ia/IIa, Ib/IX, IV, CD109, and HLA class I were present on the surface of the lyophilised platelets at a comparable level to that of fresh platelets. The consistent results obtained with WHO reference reagents containing anti-HPA-1a, anti-HPA-3a, and anti-HPA-5b, as well as clinical samples from the same donors containing anti-HLA antibodies when reacting with lyophilised versus fresh platelets confirmed good antigenicity preservation of platelets after freeze-drying. Further investigation showed that the lyophilised platelets could be stored at 2-8 °C for up to 14 months and the reconstituted suspension was stable for 48 h. Therefore, lyophilised platelets can be a convenient alternative to fresh platelets to use for anti-platelet antibody detection in SPRCA tests., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
17. Report on the 19th International Society of Blood Transfusion Platelet Immunology Workshop 2018.
- Author
-
Lewin A, Al Khan S, Beaudin L, Meilleur L, Clarke G, and Richard L
- Subjects
- Humans, Immunologic Tests, Integrin beta3, Laboratories, Sensitivity and Specificity, Antigens, Human Platelet immunology, Blood Platelets immunology, Blood Transfusion, Isoantibodies blood
- Abstract
Background and Objectives: The aims of the 19th International Society of Blood Transfusion Platelet Immunology Workshop were to compare the sensitivity and specificity of in-house and commercially available methods for the detection of alloantibodies against human platelet antigens. Survey regarding laboratory management of samples collected for the diagnosis of foetal neonatal alloimmune thrombocytopenia was also conducted., Materials and Methods: Twenty-nine laboratories from 17 countries were invited to participate. Seven serum or plasma samples for antibody identification and eight DNA samples for genotyping were sent to participating laboratories. Additionally, samples, critical reagents, materials and instructions for three exercises, one using a commercial kit (Pak Lx), one on platelet preparation for the detection of anti-HPA-3 antibodies and one for testing four anti-CD109 monoclonal antibodies for anti-HPA-15 antibody detection, were provided., Results: Anti-HPA-1a, anti-HPA-2b, anti-HPA-5b and anti-GPIV were detected by the majority of the 28 reporting laboratories using their respective in-house MAIPA assay and/or a commercially available assay. Conversely, very few laboratories correctly identified anti-HPA-3a and HPA-15b. DNA genotyping of HPA and HLA alleles was highly accurate, with just a few discrepancies relative to the expected results. The Pak Lx kit has proven reliable for detecting anti-HPA-1a, anti-HPA-5a and anti-HLA; however, it failed at identifying an anti-HPA-3a in a clinical sample., Conclusions: Some anti-platelet alloantibodies are reliably and consistently detected, yet others remain difficult to detect. Genotyping of HPA and HLA alleles has proven to be highly accurate and robust. Future work should focus on optimizing the detection of anti-HPA-3 and anti-HPA-15 antibodies., (© 2020 International Society of Blood Transfusion.)
- Published
- 2020
- Full Text
- View/download PDF
18. Fetal and Neonatal Alloimmune Thrombocytopenia-New Prospects for Fetal Risk Assessment of HPA-1a-Negative Pregnant Women.
- Author
-
Kjeldsen-Kragh J and Bengtsson J
- Subjects
- Biomarkers blood, Female, Humans, Infant, Newborn, Pregnancy, Risk Assessment, Thrombocytopenia, Neonatal Alloimmune blood, Thrombocytopenia, Neonatal Alloimmune prevention & control, Antigens, Human Platelet immunology, HLA-DRB3 Chains immunology, Integrin beta3 immunology, Isoantibodies blood, Prenatal Care methods, Thrombocytopenia, Neonatal Alloimmune diagnosis, Thrombocytopenia, Neonatal Alloimmune immunology
- Abstract
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare and potentially serious bleeding condition in the fetus/newborn. FNAIT is usually considered as the platelet counterpart of hemolytic disease of the fetus and newborn. In FNAIT, maternal alloantibodies against paternally inherited platelet antigens traverse the placenta and cause thrombocytopenia in the fetus/newborn. The most common and most serious cases of FNAIT among white people are caused by alloantibodies against the human platelet antigen 1a (HPA-1a), which is absent in 2.3% of women. Today, there is no screening for FNAIT, and for this reason, FNAIT is not suspected until an otherwise healthy child, born at term, presents with thrombocytopenia. Clinical management of subsequent pregnancies at risk of FNAIT is mostly based on the obstetric history. During the last 5 decades, hemolytic disease of the fetus and newborn caused by antibodies against RhD has successfully been prevented by administration of hyperimmune anti-D IgG drug products to RhD-negative women after delivery of an RhD-positive child. Similarly, a hyperimmune anti-HPA-1a IgG (NAITgam) is under development for the prevention of HPA-1a immunization and FNAIT. If NAITgam becomes licensed for FNAIT prophylaxis and national health authorities decide to include FNAIT screening in their antenatal health care programs, it will be necessary to improve today's tools for assessing the risk of FNAIT. Although the primary risk factor for HPA-1a immunization is platelet type HPA-1bb, not all HPA-1a-negative women develop anti-HPA-1a. The women who are HLA-DRB3:01:01 negative (72%) only rarely develop anti-HPA-1a, and for those few who become HPA-1a immunized, it is quite rare to have a child with severe thrombocytopenia. Determination of fetal HPA-1 type is important because 15% of HPA-1a-negative women will carry an HPA-1a-negative fetus and therefore not be at risk of FNAIT. The severity of FNAIT seems to be associated with the level of anti-HPA-1a. Hence, in Norway, for example, an Ab threshold of 3 IU/mL is used to distinguish between low- and high-risk pregnancies. The current review will discuss to what extent these analyses, as well as determination of subtypes of anti-HPA-1a (anti-β3, anti-αIIbβ3, and anti-αvβ3) and Fc core fucosylation of anti-HPA-1a IgG, can be used as risk stratification tools., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
19. Passenger lymphocyte thrombocytopenia due to human platelet antigen 3a antibodies: Case report and review of literature.
- Author
-
French W, Hopkins M, Poles A, and Mijovic A
- Subjects
- Adult, Female, Humans, Male, Thrombocytopenia etiology, Thrombocytopenia immunology, Antigens, Human Platelet immunology, Immunoglobulin G administration & dosage, Isoantibodies immunology, Liver Transplantation, Thrombocytopenia drug therapy
- Abstract
We report a case of severe acute thrombocytopenia occurring within days after a cadaveric liver transplant, received from a female patient with aplastic anemia who died of intracranial bleeding. The donor, who was homozygous for the ITGA2B*002 (HPA-3b) gene, had developed human platelet antigen (HPA)-3a antibodies, whereas the recipient was homozygous for the ITGA2B*001 (HPA-3a) gene. Thrombocytopenia responded to an infusion of immunoglobulin G. This is the first report of a passenger lymphocyte syndrome manifesting with thrombocytopenia due to anti-HPA-3a. We review the literature on thrombocytopenia in the setting of PLS and discuss the differential diagnosis., (© 2020 AABB.)
- Published
- 2020
- Full Text
- View/download PDF
20. Evolution and Utility of Antiplatelet Autoantibody Testing in Patients with Immune Thrombocytopenia.
- Author
-
Porcelijn L, Schmidt DE, Oldert G, Hofstede-van Egmond S, Kapur R, Zwaginga JJ, and de Haas M
- Subjects
- Autoimmune Diseases blood, Biomarkers blood, Blood Platelets metabolism, Glycoproteins blood, Glycoproteins immunology, Humans, Sensitivity and Specificity, Thrombocytopenia blood, Antigens, Human Platelet immunology, Autoantibodies blood, Autoimmune Diseases diagnosis, Autoimmune Diseases immunology, Blood Platelets immunology, Thrombocytopenia diagnosis, Thrombocytopenia immunology
- Abstract
To this day, immune thrombocytopenia (ITP) remains a clinical diagnosis made by exclusion of other causes for thrombocytopenia. Reliable detection of platelet autoantibodies would support the clinical diagnosis, but the lack of specificity and sensitivity of the available methods for platelet autoantibody testing limits their value in the diagnostic workup of thrombocytopenia. The introduction of methods for glycoprotein-specific autoantibody detection has improved the specificity of testing and is acceptable for ruling in ITP but not ruling it out as a diagnosis. The sensitivity of these assays varies widely, even between studies using comparable assays. A review of the relevant literature combined with our own laboratory's experience of testing large number of serum and platelet samples makes it clear that this variation can be explained by variations in the characteristics of the tests, including in the glycoprotein-specific monoclonal antibodies, the glycoproteins that are tested, the platelet numbers used in the assay and the cutoff levels for positive and negative results, as well as differences in the tested patient populations. In our opinion, further standardization and optimization of the direct autoantibody detection methods to increase sensitivity without compromising specificity seem possible but will still likely be insufficient to distinguish the often very weak specific autoantibody signals from background signals. Further developments of autoantibody detection methods will therefore be necessary to increase sensitivity to a level acceptable to provide laboratory confirmation of a diagnosis of ITP., (Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
21. Successful management of a pregnant woman with severe ANKRD26 -related thrombocytopenia and anti-HPA-5b alloimmunization.
- Author
-
Lazaro E, Houssin C, Sentilhes L, Blouin L, and Fiore M
- Subjects
- 5' Untranslated Regions, Adult, Biomarkers, Blood Coagulation, Blood Coagulation Tests, Disease Management, Disease Susceptibility, Female, Genetic Association Studies, Genetic Predisposition to Disease, Germ-Line Mutation, Humans, Intercellular Signaling Peptides and Proteins metabolism, Pregnancy, Pregnancy Complications, Hematologic diagnosis, Thrombocytopenia diagnosis, Antigens, Human Platelet immunology, Intercellular Signaling Peptides and Proteins genetics, Isoantibodies immunology, Pregnancy Complications, Hematologic etiology, Pregnancy Complications, Hematologic therapy, Thrombocytopenia etiology, Thrombocytopenia therapy
- Published
- 2020
- Full Text
- View/download PDF
22. HIP (HPA-screening in pregnancy) study: protocol of a nationwide, prospective and observational study to assess incidence and natural history of fetal/neonatal alloimmune thrombocytopenia and identifying pregnancies at risk.
- Author
-
Winkelhorst D, de Vos TW, Kamphuis MM, Porcelijn L, Lopriore E, Oepkes D, van der Schoot CE, and de Haas M
- Subjects
- Female, Humans, Incidence, Infant, Newborn, Pregnancy, Prenatal Care, Prospective Studies, Research Design, Risk Assessment, Thrombocytopenia, Neonatal Alloimmune blood, Antigens, Human Platelet immunology, Isoantibodies blood, Maternal Serum Screening Tests, Observational Studies as Topic, Thrombocytopenia, Neonatal Alloimmune diagnosis
- Abstract
Introduction: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) may lead to severe fetal or neonatal bleeding and/or perinatal death. Maternal alloantibodies, targeted against fetal human platelet antigens (HPAs), can result thrombocytopenia and bleeding complications. In pregnancies with known immunisation, fetal bleeding can be prevented by weekly maternal intravenous immunoglobulin infusions. Without population-based screening, immunisation is only detected after birth of an affected infant. Affected cases that might have been prevented, when timely identified through population-based screening. Implementation is hampered by the lack of knowledge on incidence, natural history and identification of pregnancies at high risk of bleeding. We designed a study aimed to obtain this missing knowledge., Methods and Analysis: The HIP (HPA-screening in pregnancy) study is a nationwide, prospective and observational cohort study aimed to assess incidence and natural history of FNAIT as well as identifying pregnancies at high risk for developing bleeding complications. For logistic reasons, we invite rhesus D-negative or rhesus c-negative pregnant women, who take part in the Dutch population-based prenatal screening programme for erythrocyte immunisation, to participate in our study. Serological HPA-1a typing is performed and a luminex-based multiplex assay will be performed for the detection of anti-HPA-1a antibodies. Results will not be communicated to patients or caregivers. Clinical data of HPA-1a negative women and an HPA-1a positive control group will be collected after birth. Samples of HPA-1a immunised pregnancies with and without signs of bleeding will be compared with identify parameters for identification of pregnancies at high risk for bleeding complications., Ethics and Dissemination: Ethical approval for this study has been obtained from the Medical Ethical Committee Leiden-The Hague-Delft (P16.002). Study enrolment began in March 2017. All pregnant women have to give informed consent for testing according to the protocol. Results of the study will be disseminated through congresses and publication in relevant peer-reviewed journals., Trial Registration Number: NCT04067375., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF
23. The prevalence of HPA-1a alloimmunization and the potential risk of FNAIT depend on both the DRB3*01:01 allele and associated DR-DQ haplotypes.
- Author
-
Ahlen MT, Heide G, Husebekk A, Skogen B, Kjeldsen-Kragh J, and Stuge TB
- Subjects
- Female, Gene Frequency genetics, Genotyping Techniques, Haplotypes genetics, Humans, Infant, Newborn, Integrin beta3, Pregnancy, Thrombocytopenia, Neonatal Alloimmune immunology, Thrombocytopenia, Neonatal Alloimmune pathology, Antigens, Human Platelet immunology, Genetic Predisposition to Disease genetics, HLA-DQ Antigens genetics, HLA-DRB3 Chains genetics, Thrombocytopenia, Neonatal Alloimmune genetics
- Abstract
Alloimmunization against human platelet antigen (HPA)-1a during pregnancy can cause foetal/neonatal alloimmune thrombocytopenia (FNAIT) and severe bleeding in the foetus or newborn and likely depends on several factors. HPA-1a alloimmunization is associated with DRB3*01:01, which is associated with several DR-DQ haplotypes. However, it is not known to what extent these haplotypes contribute to the prevalence of HPA-1a alloimmunization. HPA-1a-alloimmunized women, identified in a prospective study, and random donors were typed for selected DRB3, DRB4, DRB1, DQA1 and DQB1 alleles to determine allele and DR-DQ haplotype frequencies. DRB3*01:01 was carried by 94% HPA-1a-immunized women compared to 27% in the general population. In the first population, the DR3-DQ2 haplotype was overrepresented (P < .003). The prevalence of HPA-1a alloimmunization was estimated to be about twice as frequent with DR3-DQ2 compared to DR13-DQ6, together accounting for about 90% of DRB3*01:01-positive individuals. Further, we examined DQB1*02 and DRB4*01:01 alleles for their reported association with HPA-1a alloimmunization, in the context of DR-DQ haplotypes. Since ~ 80% of DQB1*02 alleles are linked to the DR3-DQ2 haplotype, the association might be coincidental. However, the DQB1*02:02-associated DR7-DQ2 haplotype was also overrepresented in alloimmunized women, suggesting a role for this allele or haplotype in HPA-1a alloimmunization. As DRB4*01:01 is predominantly associated with the DR7-DQ2 haplotype in HPA-1a-alloimmunized individuals, the reported association with FNAIT may be coincidental. Typing for DR-DQ haplotypes revealed important genetic associations with HPA-1a alloimmunization not evident from typing individual alleles, and the presence of different DRB3-associated DR-DQ haplotypes showed different prevalence of HPA-1a alloimmunization., (© 2020 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.)
- Published
- 2020
- Full Text
- View/download PDF
24. Thrombocytopenia and Thromboses in Myocardial Infarction Associated with Eptifibatide-Dependent Activating Antiplatelet Antibodies.
- Author
-
Puram RV, Erdil RM, Weber BN, Knelson EH, Van Beuningen AM, Wallwork R, Gilyard SN, Curtis BR, Ranganathan R, Leaf RK, and Malhotra R
- Subjects
- Arginine analogs & derivatives, Arginine therapeutic use, Aspirin therapeutic use, Combined Modality Therapy, Coronary Thrombosis etiology, Coronary Thrombosis surgery, Drug Substitution, Drug Therapy, Combination, Eptifibatide immunology, Eptifibatide therapeutic use, Humans, Male, Middle Aged, Percutaneous Coronary Intervention, Pipecolic Acids therapeutic use, Platelet Aggregation Inhibitors immunology, Platelet Aggregation Inhibitors therapeutic use, Platelet Glycoprotein GPIIb-IIIa Complex immunology, Platelet Transfusion, Purpura, Thrombocytopenic, Idiopathic immunology, Purpura, Thrombocytopenic, Idiopathic therapy, ST Elevation Myocardial Infarction drug therapy, ST Elevation Myocardial Infarction therapy, Shock, Cardiogenic etiology, Stents adverse effects, Sulfonamides therapeutic use, Thrombectomy, Thrombolytic Therapy, Thrombosis drug therapy, Ticagrelor therapeutic use, Warfarin therapeutic use, Antigens, Human Platelet immunology, Autoantibodies immunology, Eptifibatide adverse effects, Platelet Aggregation Inhibitors adverse effects, Platelet Glycoprotein GPIIb-IIIa Complex antagonists & inhibitors, Purpura, Thrombocytopenic, Idiopathic etiology, ST Elevation Myocardial Infarction blood, Thrombosis etiology
- Abstract
Competing Interests: None declared.
- Published
- 2020
- Full Text
- View/download PDF
25. Diagnosis and treatment of immunological platelet refractoriness by histocompatibility.
- Author
-
Fagundes IS, Franz JM, Jobim MS, Arend A, Merzoni J, Cardone JM, Gil B, Sekine L, and Jobim LF
- Subjects
- Blood Donors, Humans, Platelet Count, Platelet Transfusion methods, Retrospective Studies, Thrombocytopenia therapy, Transfusion Reaction, Antibodies immunology, Antigens, Human Platelet immunology, Blood Grouping and Crossmatching methods, Blood Platelets immunology, HLA Antigens immunology, Histocompatibility, Histocompatibility Antigens Class I immunology
- Abstract
Immunological platelet refractoriness occurs when polytransfused patients develop antibodies against donors' HLA class I antigens, HPA (human platelet antigens) and few cases against both systems. Flow cytometry crossmatch with the patient serum against platelets from several donors can determine whether the refractoriness is or is not of immunological origin. Patients with moderate sensitization will be given transfusions from donors with a negative platelets crossmatch; those who are hypersensitized will need to have antibodies assessed against a reactivity panel (RP) for HLA class I and HPA. The patient must be typed for HLA and HPA in order to identify best donors. We have compiled a list of 500 donors registered at our blood bank with known HLA and HPA profiles. Pre-transfusion crossmatch is performed against donors selected virtually, transfusing those who are negative. We analyzed 75 patients with refractoriness, 67% (50/75) of whom had anti-HLA or anti-HPA antibodies and 56% (28/50) were hypersensitized, with RP ≥ 80%. The diagnosis of the immunological refractoriness and the compatibility between donor and recipient allowed efficient transfusions for all patients., (Copyright © 2020 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
26. Foetal and neonatal alloimmune thrombocytopenia - The role of the HLA-DRB3*01:01 allele for HPA-1a-immunisation and foetal/neonatal outcome.
- Author
-
Kjeldsen-Kragh J and Ahlen MT
- Subjects
- Alleles, Fetus, Humans, Integrin beta3, Antigens, Human Platelet immunology, HLA-DRB3 Chains immunology, Isoantibodies immunology, Thrombocytopenia, Neonatal Alloimmune immunology
- Abstract
Foetal and neonatal alloimmune thrombocytopenia (FNAIT) is the platelet counterpart of haemolytic disease of the foetus and newborn. Among Caucasians, around 80 % of FNAIT cases and some of the most severe cases, are caused by alloantibodies against the human platelet antigen 1a (HPA-1a). For around 3 decades it has been known that almost all HPA-1a-immunised women are HLA-DRB3*01:01 positive. The HLA molecule encoded by the HLA-DRA/DRB3*01:01 genes seems to be of crucial importance for initiating the immune response against HPA-1a. The HLA-DRB3*01:01 carrier status is not only important as a risk factor for immunisation, but does also have a significant impact on foetal/neonatal outcome. The possible role of HLA-DRB3*01:01 typing as tool for risk stratification is discussed., Competing Interests: Declaration of Competing Interest JKK belong to a group of founders and owners of Prophylix AS, a Norwegian biotech company which has produced a hyperimmune anti-HPA-1a IgG (NAITgam) for the prevention of HPA-1a-immunisation and FNAIT. JKK is also a consultant for Rallybio IPA, LLC a US biotech company which will continue the development of NAITgam until licensure., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
27. Recent advances in non-invasive fetal HPA-1a typing.
- Author
-
Nogués N
- Subjects
- Female, Fetus, Humans, Integrin beta3, Pregnancy, Antigens, Human Platelet immunology, Thrombocytopenia, Neonatal Alloimmune immunology
- Abstract
Non-invasive fetal HPA-1a typing is a valuable tool to identify the pregnancies at risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). At present, prenatal determination of the fetus HPA-1a type is performed for diagnostic purposes in pregnancies of HPA-1 alloimmunized women with history of a previous fetus or child with FNAIT. Different approaches have been used to determine the fetal HPA-1a genotype from cell-free fetal DNA (cffDNA) in the mother's plasma, mainly based on real-time PCR. Due to the single nucleotide polymorphism (SNP) between the HPA-1a and HPA-1b allelic sequences, a robust and accurate detection of the fetal genotype is challenging, and the sensitivity of most assays is still limited early in pregnancy. Nowadays, the availability of technologies such as next generation sequencing (NGS) or digital PCR offers unprecedented possibilities of analyzing cell-free DNA (cfDNA)-amplified sequences with very high coverage and high sensitivity. In addition, other interesting approaches using variant sequence enrichment strategies have been recently described. In particular, coamplification at lower denaturation temperature PCR (COLD-PCR) offers a simple and sensitive strategy for noninvasive fetal HPA-1 typing. These novel approaches are explained in more detail in this review. Despite no population-based FNAIT screening programs have so far been implemented, the perspectives in terms of treatment and prevention are changing and less costly high-throughput maternal HPA-1a typing methods have been developed. Altogether, this may lead to the implementation of fetal HPA-1a typing with a broader scope in the future, playing a critical role within FNAIT screening programs., Competing Interests: Declaration of Competing Interest None., (Copyright © 2020 The Author. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
28. Fetal and neonatal alloimmune thrombocytopenia - The Norwegian management model.
- Author
-
Tiller H, Ahlen MT, Akkök ÇA, and Husebekk A
- Subjects
- Female, Fetus, Humans, Infant, Newborn, Integrin beta3, Norway, Pregnancy, Antigens, Human Platelet immunology, Thrombocytopenia, Neonatal Alloimmune immunology
- Abstract
In Norway, the management strategy for fetal and neonatal alloimmune thrombocytopenia (FNAIT) has for more than two decades differed from most other countries. The focus of this paper is to describe and discuss the Norwegian FNAIT management program. We recommend antenatal IVIg to women who previously have had a child with FNAIT-induced ICH, and usually not to HPA-1a alloimmunized pregnant women where a previous child had FNAIT, but not ICH. When deciding management strategy, we use not only the obstetric history but also the antenatal anti-HPA-1a antibody level as a tool for risk stratification. The Norwegian National Unit for Platelet Immunology (NNUPI) at the University Hospital of North Norway in Tromsø provides diagnostic and consulting service for the clinicians and the blood banks all over the country, and serves as a national reference laboratory for FNAIT investigations., Competing Interests: Declaration of Competing Interest AH belong to the group of founders and owners of Prophylix AS, a Norwegian biotech company, which has been developing a hyperimmune anti-HPA-1a IgG for the prevention of fetal and neonatal alloimmune thrombocytopenia. The assets of Prophylix AS were recently acquired by Rallybio IPA, LLC. The remaining authors declare no competing financial interests., (Copyright © 2019 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
29. Strategies to develop a prophylaxis for the prevention of HPA-1a immunization and fetal and neonatal alloimmune thrombocytopenia.
- Author
-
Kjær M, Geisen C, Akkök ÇA, Wikman A, Sachs U, Bussel JB, Nielsen K, Walles K, Curtis BR, Vidarsson G, Järås K, and Skogen B
- Subjects
- Female, Fetus, Humans, Infant, Newborn, Integrin beta3, Pregnancy, Antigens, Human Platelet immunology, Thrombocytopenia, Neonatal Alloimmune immunology, Thrombocytopenia, Neonatal Alloimmune prevention & control
- Abstract
Anti-HPA-1a-antibodies are the main cause of fetal and neonatal alloimmune thrombocytopenia (FNAIT) which may result in intracranial hemorrhage (ICH) and death among fetuses and newborns. Advances in understanding the pathogenesis of FNAIT and proof of concept for prophylaxis to prevent immunization suggest that development of hyperimmune anti-HPA-1a IgG aimed at preventing immunization against HPA-1a and FNAIT is feasible. Anti-HPA-1a IgG can be obtained either by isolating immunoglobulin from already-immunized women or by development of monoclonal anti-HPA-1a antibodies. Here we discuss recent advances that may lead to the development of a prenatal and postnatal prophylactic treatment for the prevention of HPA-1a-associated FNAIT and life-threatening FNAIT-induced complications., Competing Interests: Declaration of Competing Interest MK and BS belong to a group of founders and owners of Prophylix AS, a Norwegian biotech company that produced hyperimmune anti-HPA-1a IgG (NAITgam) April 2019. Further, MK and JB are consultants for Rallybio, a US biotech company that will continue development of NAITgam for prevention FNAIT., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
30. Identifying human leukocyte antigen (HLA)-compatible platelets using the Matchmaker programme in alloimmunised platelet-refractory patients.
- Author
-
Kreuter JD
- Subjects
- Humans, Antigens, Human Platelet immunology, Blood Platelets immunology, HLA Antigens immunology, Histocompatibility, Platelet Transfusion
- Published
- 2020
- Full Text
- View/download PDF
31. Prospects for risk stratification of anti-HPA-1a alloimmunized pregnant women.
- Author
-
Sachs UJ
- Subjects
- Female, Humans, Integrin beta3, Pregnancy, Risk Assessment, Antigens, Human Platelet immunology
- Abstract
A diagnosis of fetal/neonatal alloimmune thrombocytopenia (FNAIT) is made if a platelet-specific antibody is detected in the mother and the fetus or newborn carries the cognate antigen. Some children will experience very low platelet counts or even intracranial hemorrhage with devastating consequences, whereas others are largely unaffected. At the moment, predictive tools to forecast the severity of FNAIT during pregnancy are not available and over- or under-treatment may put the mother or the fetus at risk. A number of potential modulators of FNAIT severity have been reported. Maternal immune responses differ in respect to the IgG subtype composition, the glycosylation pattern of the antibodies, their fine specificity, and their functional effects on platelets, the trophoblast, and endothelial cells. In addition, antibody levels are variable. The efficacy of IgG transfer and, on the fetal side, gender and inflammatory responses, were also investigated for their potential impact on FNAIT severity. These potential risk modulators are scrutinized for available experimental and clinical evidence. Antibody glycosylation and anti-endothelial activity are hot candidates which, most likely in conjunction with the antibody level, should be explored further as tools to stratify fetal risk., Competing Interests: Declaration of Competing Interest None., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
32. Bioengineered iPSC-derived megakaryocytes for the detection of platelet-specific patient alloantibodies.
- Author
-
Zhang N, Santoso S, Aster RH, Curtis BR, and Newman PJ
- Subjects
- Antigens, Human Platelet genetics, Antigens, Human Platelet metabolism, Flow Cytometry, Humans, Induced Pluripotent Stem Cells metabolism, Isoantibodies blood, Megakaryocytes metabolism, Antigens, Human Platelet immunology, Cell Engineering, Induced Pluripotent Stem Cells immunology, Isoantibodies immunology, Megakaryocytes immunology
- Abstract
Human platelet membrane glycoprotein polymorphisms can be immunogenic in man and are frequently the cause of clinically important immune reactions responsible for disorders such as neonatal alloimmune thrombocytopenia. Platelets from individuals carrying rare polymorphisms are often difficult to obtain, making diagnostic testing and transfusion of matched platelets challenging. In addition, class I HLA antibodies frequently present in maternal sera interfere with the detection of platelet-reactive alloantibodies. Detection of alloantibodies to human platelet antigen 3 (HPA-3) and HPA-9 is especially challenging, in part because of the presence of cell type-specific glycans situated near the polymorphic amino acid that together form the alloepitope. To overcome these limitations, we generated a series of HLA class I-negative blood group O induced pluripotent stem cell (iPSC) lines that were gene edited to sequentially convert their endogenous HPA-3a alloantigenic epitope to HPA-3b, and HPA-9a to HPA-9b. Subjecting these cell lines, upon differentiation into CD41+/CD42b+ human megakaryocytes (MKs), to flow cytometric detection of suspected anti-HPA-3 and HPA-9 alloantisera revealed that the HPA-3a-positive MKs specifically reacted with HPA-3a patient sera, whereas the HPA-3b MKs lost reactivity with HPA-3a patient sera while acquiring reactivity to HPA-3b patient sera. Importantly, HPA-9b-expressing MKs specifically reacted with anti-HPA-9b-suspected patient samples that had been undetectable using conventional techniques. The provision of specialized iPSC-derived human MKs expressing intact homozygous glycoprotein alloantigens on the cell surface that carry the appropriate endogenous carbohydrate moieties should greatly enhance detection of clinically important and rare HPA-specific alloantibodies that, to date, have resisted detection using current methods., (© 2019 by The American Society of Hematology.)
- Published
- 2019
- Full Text
- View/download PDF
33. Thioacetamide-induced liver damage and thrombocytopenia is associated with induction of antiplatelet autoantibody in mice.
- Author
-
Lin YY, Hu CT, Sun DS, Lien TS, and Chang HH
- Subjects
- Animals, Chemical and Drug Induced Liver Injury complications, Disease Models, Animal, Disease Progression, Humans, Male, Mice, Rats, Thrombocytopenia chemically induced, Tumor Necrosis Factor-alpha metabolism, Antigens, Human Platelet immunology, Autoantibodies metabolism, Chemical and Drug Induced Liver Injury immunology, Thioacetamide adverse effects, Thrombocytopenia immunology
- Abstract
Thrombocytopenia is usually associated with liver injury, elevated plasma aspartate aminotransferase and alanine aminotransferase levels, and high antiplatelet immunoglobulin (Ig) titers, although the mechanism behind these effects remains elusive. Deciphering the mechanism behind acute liver disease-associated thrombocytopenia may help solve difficulties in routine patient care, such as liver biopsy, antiviral therapy, and surgery. To determine whether liver damage is sufficient per se to elicit thrombocytopenia, thioacetamide (TAA)-induced hepatitis rodent models were employed. The analysis results indicated that TAA treatment transiently induced an elevation of antiplatelet antibody titer in both rats and mice. B-cell-deficient (BCD) mice, which have loss of antibody expression, exhibited markedly less thrombocytopenia and liver damage than wild-type controls. Because TAA still induces liver damage in BCD mice, this suggests that antiplatelet Ig is one of the pathogenic factors, which play exacerbating role in the acute phase of TAA-induced hepatitis. TNF-α was differentially regulated in wild-type versus BCD mice during TAA treatment, and anti-TNF treatment drastically ameliorated antiplatelet Ig induction, thrombocytopenia, and liver injury, suggesting that the TNF pathway plays a critical role in the disease progression.
- Published
- 2019
- Full Text
- View/download PDF
34. Current Anti-HPA-1a Standard Antibodies React with the β3 Integrin Subunit but not with αIIbβ3 and αvβ3 Complexes.
- Author
-
Bayat B, Traum A, Berghöfer H, Werth S, Zhu J, Bein G, Sachs UJ, and Santoso S
- Subjects
- Endothelial Cells immunology, HEK293 Cells, Humans, Isoantibodies blood, Neovascularization, Physiologic, Predictive Value of Tests, Reproducibility of Results, Severity of Illness Index, Thrombocytopenia, Neonatal Alloimmune blood, Thrombocytopenia, Neonatal Alloimmune immunology, Antibodies, Monoclonal immunology, Antibody Specificity, Antigens, Human Platelet immunology, Immunologic Tests, Integrin alphaVbeta3 immunology, Integrin beta3 immunology, Isoantibodies immunology, Platelet Glycoprotein GPIIb-IIIa Complex immunology, Thrombocytopenia, Neonatal Alloimmune diagnosis
- Abstract
Background: Fetal/neonatal alloimmune thrombocytopenia (FNAIT) results from maternal alloantibodies (abs) reacting with fetal platelets expressing paternal human platelet antigens (HPAs), mostly HPA-1a. Anti-HPA-1a abs, are the most frequent cause of severe thrombocytopenia and intracranial hemorrhage (ICH)., Objectives: Titration of anti-HPA-1a in maternal serum using standard National Institute for Biological Standards and Control (NIBSC) 03/152 is one diagnostic approach to predict the severity of FNAIT. Recently, we found three anti-HPA-1a subtypes reacting with the β3 subunit independently or dependently from complexes with αIIb and αv. Endothelial cell-reactive anti-αvβ3 abs were found predominantly in cases with ICH. Our aim was to assess whether available standard material represents all anti-HPA-1a subtypes., Materials and Methods: In this study, anti-HPA-1a sera (NIBSC 03/152) and human monoclonal antibodies (moabs) against HPA-1a (moabs 26.4 and 813) were evaluated using transfected cell lines expressing αIIbβ3, αvβ3 or monomeric cβ3., Results: Flow cytometry analyses with well-characterized murine moabs recognizing αIIbβ3, αvβ3, or β3 alone demonstrated that AP3 reacts compound-independently, whereas compound-dependent moabs Gi5 and 23C6 reacted only with complexes. NIBSC 03/152, moabs 26.4, and 813 against HPA-1a reacted like AP3, same results were obtained with monomeric cβ3 in immunoblotting. Antigen capture assay targeting endothelial cells showed anti-HPA-1a reactivity disappearance after cβ3 beads adsorption. Furthermore, in contrast to anti-HPA-1a abs from ICH cases, none of NIBSC 03/152, 26.4, and 813 inhibited tube formation., Conclusion: These results suggest that current anti-HPA-1a standard material contains only the anti-β3 subtype. The absence of anti-αvβ3 makes NIBSC 03/152 less suitable as standard to predict the severity of FNAIT., Competing Interests: None declared., (Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2019
- Full Text
- View/download PDF
35. Role of complement in patients with autoimmune hemolytic anemia and platelet transfusion refractoriness.
- Author
-
Fontaine MJ
- Subjects
- Anemia, Hemolytic, Autoimmune therapy, Antibody Specificity, Antigens, Human Platelet immunology, Antilymphocyte Serum blood, Antilymphocyte Serum immunology, Autoantibodies blood, Autoantibodies immunology, Humans, Immunoglobulin G immunology, Immunoglobulin M immunology, Anemia, Hemolytic, Autoimmune immunology, Complement System Proteins immunology, Immunity, Innate immunology, Platelet Transfusion
- Abstract
The complement is a key player of the innate immune response. It provides defense mechanisms that are not specific, but very efficient at neutralizing any invader, accounting for 4% of the proteins in the peripheral blood. Nevertheless, there is a dark side to the complement system, as it may activate its machinery against healthy cells such as peripheral blood red blood cells and platelets resulting in undesired hemolysis and thrombocytopenia, respectively. Understanding and identifying the role of complement in these settings allow physicians to adjust their diagnostic and therapeutic modalities accordingly. The role of complement in the pathophysiology and management of autoimmune hemolytic anemia and of alloimmune-mediated thrombocytopenia is under investigation and discussed., (Copyright © 2019 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
36. Maternal sensitization occurs before delivery in severe cases of fetal alloimmune thrombocytopenia.
- Author
-
Jin JC, Lakkaraja MM, Ferd P, Manotas K, Gabor J, Wissert M, Berkowitz RL, McFarland JG, and Bussel JB
- Subjects
- Adult, Female, Humans, Infant, Newborn, Integrin beta3, Pregnancy immunology, Severity of Illness Index, Young Adult, Antigens, Human Platelet immunology, Histocompatibility, Maternal-Fetal immunology, Maternal-Fetal Exchange immunology, Thrombocytopenia, Neonatal Alloimmune immunology
- Published
- 2019
- Full Text
- View/download PDF
37. Fetal thrombocytopenia in pregnancies complicated by fetal anemia due to red-cell alloimmunization: cohort study and meta-analysis.
- Author
-
Rosenbloom JI, Bruno AM, Conner SN, Tuuli MG, Simon LE, Macones GA, and Cahill AG
- Subjects
- Anemia diagnosis, Anemia etiology, Antigens, Human Platelet immunology, Female, Fetoscopy, Gestational Age, Humans, Platelet Count, Pregnancy, Pregnancy Complications, Hematologic, Retrospective Studies, Thrombocytopenia diagnosis, Thrombocytopenia immunology, Blood Group Incompatibility complications, Fetal Blood cytology, Fetal Diseases etiology, Thrombocytopenia etiology
- Abstract
Objective: To estimate the prevalence and characteristics of fetal thrombocytopenia at the time of percutaneous umbilical cord sampling (PUBS) in pregnancies complicated by alloimmunization and to conduct a systematic review on fetal thrombocytopenia in these pregnancies., Study Design: Retrospective cohort study of all patients undergoing PUBS at our institution from 2000-2017. Clinical data, including fetal platelet counts, were abstracted from the medical record and analyzed with routine statistical procedures. A systematic review and meta-analysis were also conducted according to standard procedures., Result: At first procedure, prior to any transfusion, 13/36 fetuses (36%) had thrombocytopenia: 11/36 (31%) had moderate thrombocytopenia and 2/36 (6%) had severe thrombocytopenia (14 patients had no platelet count at first procedure). The systematic review identified six studies, and the prevalence of fetal thrombocytopenia at the time of PUBS for alloimmunization was 18% (95% confidence interval 11%, 26%)., Conclusion: Thrombocytopenia is common and underappreciated in fetuses undergoing PUBS for alloimmunization.
- Published
- 2019
- Full Text
- View/download PDF
38. Timely diagnosis and treatment of neonatal alloimmune thrombocytopenia caused by anti HPA-3a antibody: A case report.
- Author
-
Yang Q, Lv X, Kong Y, Liu X, Shao M, Zhao Y, Xia N, Wang S, and Li H
- Subjects
- Diagnosis, Differential, Humans, Immunoglobulins, Intravenous therapeutic use, Immunologic Factors therapeutic use, Infant, Newborn, Male, Thrombocytopenia, Neonatal Alloimmune immunology, Antigens, Human Platelet immunology, Autoantibodies immunology, Thrombocytopenia, Neonatal Alloimmune diagnosis, Thrombocytopenia, Neonatal Alloimmune therapy
- Abstract
Rationale: Neonatal alloimmune thrombocytopenia (NAIT) caused by anti HPA-3a antibody is rare, and the clinical features of the syndrome are not specific., Patient Concerns: A male infant was noted to be irritable and physical examination revealed the presence of petechiae and bruising on the right arm and thigh after born., Diagnoses: Platelet antibodies were investigated using the monoclonal antibody-specific immobilization of platelet antigens (MAIPA) assay, platelet genotyping (HPA 1-17) was performed by polymerase chain reaction technique with sequence-specific primers (PCR-SSP). The HPA genotype of the newborn was HPA-3a/b, while that of his mother and his father were HPA-3b/b and HPA-3a/a, respectively. The sera of newborn contained antibody against the platelet of newborn's father. The HPA antibody of the newborn was identified as anti HPA-3a. The newborn was confirmed as a patient of NAIT caused by anti HPA-3a antibody., Interventions: A single dose of intravenous immunoglobulin (IVIG) 1 g/kg was administered from day 3 to day 7., Outcomes: At follow-up 3 months after discharge from the hospital, the baby was developing normally and had a normal platelet count (361 × 109/L)., Lessons: NAIT caused by anti HPA-3a antibody is rare, and we believe this study can provide insights for diagnosing prospective cases. Prognosis of NAIT caused by HPA3a seems to be favorable if diagnosed and treated in a timely manner.
- Published
- 2019
- Full Text
- View/download PDF
39. HLA-DRB3*01:01 exhibits a dose-dependent impact on HPA-1a antibody levels in HPA-1a-immunized women.
- Author
-
Kjeldsen-Kragh J, Titze TL, Lie BA, Vaage JT, and Kjær M
- Subjects
- Adult, Female, HLA-DRB3 Chains pharmacology, Heterozygote, Homozygote, Humans, Immunization, Infant, Newborn, Integrin beta3, Platelet Count, Pregnancy, Thrombocytopenia, Neonatal Alloimmune etiology, Thrombocytopenia, Neonatal Alloimmune immunology, Antibodies drug effects, Antigens, Human Platelet immunology, HLA-DRB3 Chains genetics
- Abstract
HLA-DRB3*01:01 is a predisposing factor for human platelet antigen 1a (HPA-1a) immunization, which is responsible for most cases of fetal and neonatal alloimmune thrombocytopenia. The aim of this study was to investigate if the HLA-DRB3*01:01 allele imposes a dose-dependent effect on anti-HPA-1a levels and neonatal platelet counts. One hundred and thirty HPA-1a-immunized women were divided into 3 groups: HLA-DRB3*01:01 negative, HLA-DRB3*01:01 hemizygous or heterozygous, and HLA-DRB3*01:01 homozygous. The dose of the HLA-DRB3*01:01 allele was determined by sequencing exon 2 of the HLA-DRB3 gene followed by HLA-DRB3 and HLA-DRB1 typing of selected samples. Anti-HPA-1a levels at time of delivery and neonatal platelet counts were compared among groups. There was a significant dose-dependent effect of the HLA-DRB3*01:01 allele on anti-HPA-1a levels (global P value [ P
global ] = .0032). Median (range) anti-HPA-1a levels were 1.5 IU/mL (0.0-19.0 IU/mL), 21.1 IU/mL (0.0-1967 IU/mL), and 43.7 IU/mL (1.0-980 IU/mL) in women with 0, 1, and 2 copies of the HLA-DRB3*01:01 allele, respectively. There was also a significant, but opposite, dose-dependent effect of the mother's HLA-DRB3*01:01 allele on the platelet count of the newborn ( Pglobal = .0155). Median (range) neonatal platelet counts were 241 × 109 /L (59 × 109 /L to 393 × 109 /L), 107 × 109 /L (4 × 109 /L to 387 × 109 /L) and 32 × 109 /L (4 × 109 /L to 352 × 109 /L) for newborns of mothers with 0, 1, and 2 copies of the HLA-DRB3*01:01 allele, respectively. Thus, the HLA-DRB3*01:01 allele exhibits a dose-dependent impact on maternal anti-HPA-1a levels in HPA-1a-immunized women., (© 2019 by The American Society of Hematology.)- Published
- 2019
- Full Text
- View/download PDF
40. A case of neonatal thrombocytopenia caused by maternal alloimmunization against a new platelet antigen (Bzh a , HPA-34bw) located on GPIIIa.
- Author
-
Bertrand G, Danger Y, Laurichesse M, Verite F, and Renac V
- Subjects
- Adult, Female, Humans, Infant, Newborn, Male, Pregnancy, Antigens, Human Platelet immunology, Integrin beta3 immunology, Thrombocytopenia, Neonatal Alloimmune etiology
- Published
- 2019
- Full Text
- View/download PDF
41. Risk of HPA-1a-immunization in HPA-1a-negative women after giving birth to an HPA-1a-positive child.
- Author
-
Kjeldsen-Kragh J and Olsen KJ
- Subjects
- Female, Humans, Integrin beta3, Pregnancy, Risk Factors, Antigens, Human Platelet immunology, Immunization, Isoantibodies immunology, Parturition immunology
- Published
- 2019
- Full Text
- View/download PDF
42. Neonatal Alloimmune Thrombocytopenia: A Report of Four Cases.
- Author
-
Uenaka M, Morizane M, Tanimura K, Deguchi M, Ebina Y, Hashimoto M, Morioka I, and Yamada H
- Subjects
- Adult, Antigens, Human Platelet immunology, Female, Humans, Infant, Newborn, Integrin beta3, Platelet Transfusion, Thrombocytopenia, Neonatal Alloimmune therapy
- Abstract
Antibodies against fetal platelet alloantigens in maternal blood cause neonatal alloimmune thrombocytopenia (NAIT). We encountered four newborns with NAIT from three women. A woman carried anti-human platelet antigen (HPA)-1a antibody, and vaginally delivered a newborn who had subarachnoid hemorrhage and platelet transfusions. She delivered the second newborn by a cesarean section who had no symptom. The second woman carried anti-human leukocyte antigen-A2 antibody and vaginally delivered a newborn who had no symptom. The third woman with a history of recurrent pregnancy losses carried anti-HPA-4b antibody, and delivered a newborn by a cesarean section who received platelet transfusions and immunoglobulin infusions. Antiplatelet antibody screening may be helpful in women who have a history of blood transfusion, or previous neonates with thrombocytopenia or intracranial hemorrhage.
- Published
- 2019
43. Marked thrombocytopenia in a neonate is associated with anti-HPA-5b, anti-HLA-A31, and anti-HLA-B55 antibodies.
- Author
-
Okubo M, Nishida E, Watanabe A, Nishizaki N, Obinata K, Azuma F, Matsuhashi M, Watanabe-Okochi N, Tsuno NH, Miyake K, Yamaguchi M, Yoshida K, and Ohsaka A
- Subjects
- Adult, Female, Humans, Immunoglobulins administration & dosage, Infant, Newborn, Male, Platelet Transfusion methods, Prognosis, Thrombocytopenia, Neonatal Alloimmune pathology, Thrombocytopenia, Neonatal Alloimmune therapy, Antigens, Human Platelet immunology, HLA-A Antigens immunology, HLA-B Antigens immunology, Immunity, Maternally-Acquired immunology, Isoantibodies immunology, Thrombocytopenia, Neonatal Alloimmune immunology
- Abstract
Maternal antibodies against human platelet antigen (HPA) and/or human leukocyte antigen (HLA) cause fetal and neonatal alloimmune thrombocytopenia (FNAIT) in 0.09-0.15% of live births. Severe cases account for 5-31% and the frequency of multiple kinds of alloantibodies is 6.9-9% of FNAIT. We present a case of severe FNAIT associated with anti-HPA-5b, anti-HLA-A31, and anti-HLA-B55 antibodies, successfully treated with immunoglobulin and platelet transfusion. The anti-HLA-B55 antibody was detected in the newborn's serum, but disappeared on the 20th day, which was followed by an increase of the platelet count. These findings suggested the potential involvement of an anti-HLA antibody in the pathogenesis of FNAIT., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
44. Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review.
- Author
-
Kjaer M, Bertrand G, Bakchoul T, Massey E, Baker JM, Lieberman L, Tanael S, Greinacher A, Murphy MF, Arnold DM, Baidya S, Bussel J, Hume H, Kaplan C, Oepkes D, Ryan G, Savoia H, Shehata N, and Kjeldsen-Kragh J
- Subjects
- Antigens, Human Platelet immunology, Biomarkers blood, Female, Humans, Infant, Newborn, Integrin beta3, Maternal Serum Screening Tests methods, Platelet Count, Pregnancy, Thrombocytopenia, Neonatal Alloimmune epidemiology, Thrombocytopenia, Neonatal Alloimmune immunology, Antigens, Human Platelet blood, Thrombocytopenia, Neonatal Alloimmune blood
- Abstract
Background and Objectives: In Caucasians, fetal/neonatal alloimmune thrombocytopenia (FNAIT) is most commonly due to maternal HPA-1a antibodies. HPA-1a typing followed by screening for anti-HPA-1a antibodies in HPA-1bb women may identify first pregnancies at risk. Our goal was to review results from previous published studies to examine whether the maternal antibody level to HPA-1a could be used to identify high-risk pregnancies., Materials and Methods: The studies included were categorized by recruitment strategies: screening of unselected pregnancies or samples analyzed from known or suspected FNAIT patients., Results: Three prospective studies reported results from screening programmes, and 10 retrospective studies focused on suspected cases of FNAIT. In 8 studies samples for antibody measurement, performed by the monoclonal antibody immobilization of platelet antigen (MAIPA) assay, and samples for determining fetal/neonatal platelet count were collected simultaneously. In these 8 studies, the maternal antibody level correlated with the risk of severe thrombocytopenia. The prospective studies reported high negative predictive values (88-95%), which would allow for the use of maternal anti-HPA-1a antibody level as a predictive tool in a screening setting, in order to identify cases at low risk for FNAIT. However, due to low positive predictive values reported in prospective as well as retrospective studies (54-97%), the maternal antibody level is less suited for the final diagnosis and for guiding antenatal treatment., Conclusion: HPA-1a antibody level has the potential to predict the severity of FNAIT., (© 2018 International Society of Blood Transfusion.)
- Published
- 2019
- Full Text
- View/download PDF
45. The Immunomodulatory Activity of Polysaccharides from the Medicinal Mushroom Amauroderma rude (Agaricomycetes) Is Mediated via the iNOS and PLA2-AA Pathways.
- Author
-
Pan H, Zhao X, Lei S, Cai C, Xie YZ, and Yang X
- Subjects
- Agaricales, Animals, Cell Line, Cytokines metabolism, Enzyme-Linked Immunosorbent Assay, Mice, Tumor Necrosis Factor-alpha metabolism, Antigens, Human Platelet immunology, Immunologic Factors pharmacology, Nitric Oxide Synthase Type II immunology, Polyporaceae chemistry, Polysaccharides pharmacology, Signal Transduction drug effects
- Abstract
Our earlier work indicated that the polysaccharides of Amauroderma rude (AR) appear to have an effect on immunoregulation. However, the pathways are not clear. In this paper, we discuss the immunomodulatory mechanisms of A. rude to provide a scientific basis for its possible use as a food. Amauroderma rude increased the expression of iNOS and P38 in the Raw246.7 cell line. When the AR concentration reached 150 μg/mL, the expressions of iNOS and P38 increased 23.0% and 191.7%, respectively. When the AR concentrations were 50 μg/mL, the concentrations of cytokines IL-2, TNF-α, and IFN-γ were 33.65 pg/mL, 12.53 pg/mL and 42.56 pg/mL. When AR reached 200 μg/mL, the lgA and lgM levels were 0.73 μg/mL and 1.5 μg/mL. When AR reached 400 μg/mL, the lgG level reached 1.65 μg/mL by ELISA assay. When 4.8 mg AR were orally administered, IL-2, TNF-α, IFN-γ, PGE2, and LTB4 increased dramatically, to 0.17 pg/mL, 0.16 pg/mL, 0.15 pg/mL, 30.71 pg/mL, and 18.68 pg/mL, respectively. The concentrations of lgA, lgM, and lgG, AA, and PLA2 also increased significantly to 2.62 pg/mL, 2.14 pg/mL, 2.06 pg/mL, 5.23 μg/mL and 3.68 ng/mL, respectively. With 4.8 mg AR p.o., iNOS protein expression increased 16.8% and P38 increased 234.0%. These results indicate that A. rude polysaccharides stimulate cytokine production and activate the iNOS, PLA2-AA, and MAPK pathways during the immunomodulatory process.
- Published
- 2019
- Full Text
- View/download PDF
46. High-resolution mapping of the polyclonal immune response to the human platelet alloantigen HPA-1a (Pl A1 ).
- Author
-
Zhi H, Ahlen MT, Thinn AMM, Weiler H, Curtis BR, Skogen B, Zhu J, and Newman PJ
- Subjects
- Amino Acid Sequence, Amino Acid Substitution, Animals, Antigen-Antibody Reactions, Antigens, Human Platelet chemistry, Antigens, Human Platelet genetics, Epitope Mapping methods, Humans, Integrin beta3 chemistry, Integrin beta3 genetics, Integrin beta3 immunology, Integrin beta3 metabolism, Mice, Mice, Transgenic, Protein Domains, Protein Isoforms chemistry, Protein Isoforms genetics, Protein Isoforms immunology, Protein Isoforms metabolism, Protein Structure, Tertiary, Thrombocytopenia, Neonatal Alloimmune diagnosis, Thrombocytopenia, Neonatal Alloimmune immunology, Antibodies immunology, Antigens, Human Platelet immunology
- Abstract
Antibodies to platelet-specific antigens are responsible for 2 clinically important bleeding disorders: posttransfusion purpura and fetal/neonatal alloimmune thrombocytopenia (FNAIT). The human platelet-specific alloantigen 1a/1b (HPA-1a/1b; also known as Pl
A1/A2 ) alloantigen system of human platelet membrane glycoprotein (GP) IIIa is controlled by a Leu33Pro polymorphism and is responsible for ∼80% of the cases of FNAIT. Local residues surrounding polymorphic residue 33 are suspected to have a profound effect on alloantibody binding and subsequent downstream effector events. To define the molecular requirements for HPA-1a alloantibody binding, we generated transgenic mice that expressed murine GPIIIa (muGPIIIa) isoforms harboring select humanized residues within the plexin-semaphorin-integrin (PSI) and epidermal growth factor 1 (EGF1) domains and examined their ability to support the binding of a series of monoclonal and polyclonal HPA-1a-specific antibodies. Humanizing the PSI domain of muGPIIIa was sufficient to recreate the HPA-1a epitope recognized by some HPA-1a-specific antibodies; however, humanizing distinct amino acids within the linearly distant but conformationally close EGF1 domain was required to enable binding of others. These results reveal the previously unsuspected complex heterogeneity of the polyclonal alloimmune response to this clinically important human platelet alloantigen system. High-resolution mapping of this alloimmune response may improve diagnosis of FNAIT and should facilitate the rational design and selection of contemplated prophylactic and therapeutic anti-HPA-1a reagents., (© 2018 by The American Society of Hematology.)- Published
- 2018
- Full Text
- View/download PDF
47. Noninvasive prenatal diagnosis by cell-free DNA screening for fetomaternal HPA-1a platelet incompatibility.
- Author
-
Ferro M, Macher HC, Fornés G, Martín-Sánchez J, Jimenez-Arriscado P, Molinero P, Pérez-Simón JA, Guerrero JM, and Rubio A
- Subjects
- Adolescent, Adult, Antigens, Human Platelet immunology, Case-Control Studies, Female, Genotype, Homozygote, Humans, Integrin beta3, Polymerase Chain Reaction methods, Pregnancy, Thrombocytopenia, Neonatal Alloimmune diagnosis, Thrombocytopenia, Neonatal Alloimmune prevention & control, Young Adult, Antigens, Human Platelet blood, Cell-Free Nucleic Acids analysis, Histocompatibility, Maternal-Fetal genetics, Mass Screening methods, Prenatal Diagnosis methods
- Abstract
Background: The development of new noninvasive approaches for the diagnosis of human platelet antigen (HPA)-1 fetomaternal incompatibility has become of great interest. These approaches allow determination of whether the fetus is incompatible or not with the mother and a decision on antenatal therapy to avoid fetal or neonatal alloimmune thrombocytopenia (FNAIT). The objective of this work was to perform rapid, noninvasive prenatal test for HPA-1ab fetal antigen detection after the detection of an HPA-1-homozygous mother by using plasma cell-free DNA (cfDNA)., Study Design and Methods: The HPA-1 genotypes of 142 pregnant women and 17 nonpregnant controls were retrospectively determined by high-resolution melting (HRM) polymerase chain reaction (PCR). Coamplification at lower denaturation temperature (COLD) HRM PCR was performed to determine the fetal genotype analyzing cfDNA from all HPA-1bb pregnant women., Results: After the HRM analysis, the following genotypes were identified: HPA-1aa (71.13%), HPA-1bb (2.8%), and HPA-1ab (26.06%). Four HPA-1bb-homozygous pregnant women were carrying an incompatible fetus. Plasma samples from these mothers were analyzed by HRM COLD-PCR. Homozygous HPA-1bb pregnant women carrying an HPA-1ab-heterozygous fetus did not group with either the HPA-1ab or the HPA-1bb controls. Thus, COLD-PCR analysis allows the detection of HPA-1ab-heterozygous fetuses carried by homozygous mothers during first weeks of pregnancy., Conclusion: The fetal genotype from HPA-1bb-homozygous women was detected by a noninvasive prenatal test as soon as 12 weeks of gestation., (© 2018 AABB.)
- Published
- 2018
- Full Text
- View/download PDF
48. Posttransfusion purpura with antibodies against human platelet antigen-4a following checkpoint inhibitor therapy: a case report and review of the literature.
- Author
-
Vu K and Leavitt AD
- Subjects
- Antigens, Human Platelet blood, Antineoplastic Agents, Immunological adverse effects, Cell Cycle Checkpoints drug effects, Female, Humans, Isoantibodies adverse effects, Middle Aged, Thrombocytopenia immunology, Transfusion Reaction etiology, Antigens, Human Platelet immunology, Isoantibodies blood, Thrombocytopenia etiology, Transfusion Reaction immunology
- Abstract
Background: Posttransfusion purpura (PTP) is a rare condition characterized by severe thrombocytopenia following receipt of blood products. Most reported PTP cases involve alloantibodies directed against human platelet antigen (HPA)-1a. We present a case of PTP-mediated severe thrombocytopenia associated with alloantibodies directed against HPA-4a in the setting of combination checkpoint inhibitor therapy., Case Report: A 62-year-old woman with rectal melanoma that progressed on combination checkpoint inhibitors (ipilimumab and nivolumab) was admitted for abdominoperineal resection. She received multiple blood products during surgery, and between the sixth and eighth days post-surgery her platelet (PLT) count decreased from 126 × 10
9 /L to a nadir of 1 × 109 /L. She received intravenous immunoglobulin (IVIG), steroids, and romiplostim with eventual recovery of her PLT count to 50 × 109 /L 20 days after surgery. She tested positive for anti-HPA-4a and was shown not to express HPA-4a, confirming a diagnosis of PTP., Conclusion: Alloantibodies strongly reactive to HPA-4a were detected in this patient who received multiple blood products during abdominoperineal resection surgery. Her thrombocytopenia improved with prompt administration of IVIG, steroids, and romiplostim. PTP must always be considered in patients with acute severe thrombocytopenia after receipt of blood products, and treatment should not be delayed while awaiting laboratory confirmation. To our knowledge, this is the second reported case of PTP with antibodies against HPA-4a., (© 2018 AABB.)- Published
- 2018
- Full Text
- View/download PDF
49. Diagnostics of thrombocytopenias.
- Author
-
Mazurov AV, Khaspekova SG, and Vasiliev SA
- Subjects
- Antigens, Human Platelet blood, Antigens, Human Platelet immunology, Autoantibodies blood, Diagnosis, Differential, Humans, Platelet Count, Purpura, Thrombocytopenic, Idiopathic blood, Blood Platelets cytology, Blood Platelets immunology, Thrombocytopenia blood
- Abstract
Laboratory methods used for the diagnostics of thrombocytopenias are reviewed. Differential diagnosis is usually carried out between immune and hypoproductive forms of thrombocytopenia. Immune thrombocytopenias are caused by appearance in blood of antiplatelet abtibodies and accelerated destruction of platelets sensibilized by those antibodies, and hypoproductive thrombocytopenias - by impaired platelet production in the bone marrow. Main directions of the laboratory diagnostics of thrombocytopenias - analysis of auto- and alloautoantibodies and evaluation of platelet production and turnover in the blood stream. The following methods are used for the investigation of antiplatelet antibodies: 1) measurement of platelet associated immunoglobulins; 2) determination of circulating antibodies reacting with platelets; 3) determination of antibodies using antigen specific methods - by their reactivity with isolated platelet antigens (glycoproteins). Efficacy of platelet production could be assessed by measuring in blood the amount of "young" (reticulated) platelets. One more method for the evaluation of platelet production as well as the rate of platelet turnover - measurement of plasma soluble glycocalicin, glycoprotein Ib fragment shed from the surface of platelets upon their destruction in spleen and liver. In patients with immune thrombocytopenia autoantibodies are evaluated in all cases, the percentage of reticulated platelets is significantly increased and the amount of plasma glycocalicin is within the normal range or increased. In patients with hypoproductive thrombocytopenia autoantibodies are not detected or detected at low level, the percentage of reticulated platelets is within the normal range or slightly increased and the amount of plasma glycocalicin is lowered. Diagnostics of hapten forms of immune thromocytopenias (heparin-induced thrombocytopenia and others) and of alloimmune thrombocytopenias (neonatal alloimmune thrombocytopenia in particular) are considered in the separate sections of this review.
- Published
- 2018
- Full Text
- View/download PDF
50. Peripartum management of HLA alloimmune platelet refractoriness.
- Author
-
Peña JR, Sudhof L, and O'Brien B
- Subjects
- Adult, Antigens, Human Platelet immunology, Female, Humans, Peripartum Period, Platelet Transfusion, Pregnancy, Young Adult, HLA Antigens immunology, Thrombocytopenia immunology, Thrombocytopenia therapy
- Abstract
Background: Platelet (PLT) refractoriness presents a challenging problem for transfusion support, especially in the perioperative setting, where there is urgency for human leukocyte antigen (HLA)-compatible units, yet identification and provision of compatible PLT concentrates requires time., Case Report: A 22-year-old G3P1 woman with thrombocytopenia due to aplastic anemia, likely autoimmune, presented in her third trimester for peripartum care and newly diagnosed HLA alloimmune PLT refractoriness. Despite early planning, the patient developed bleeding requiring urgent delivery. Notably, the patient also developed strong allele-specific HLA antibody, precluding the use of HLA-matched PLTs., Results: Using full-range HLA testing services and multidisciplinary physician planning, several HLA-compatible PLT concentrates were procured to support her peripartum bleeding., Conclusion: We describe what appears to be the first reported case of management of transfusion support of PLT refractoriness peripartum. Although complicated by allele-specific HLA antibodies, using a combination of acceptable low-level antibodies and crossmatching we successfully identified HLA-compatible PLT concentrates resulting in posttransfusion PLT count increments., (© 2018 AABB.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.